Thryv Therapeutics Launches myQTwave: A First-of-its-Kind Remote Study Enabling People with Long QT Syndrome to Join Cardiac Research
Montreal, Quebec – December 1, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the launch of myQTwave, a first-of-its-kind, fully remote, app-based observational study designed to capture the lived experience of people with Long QT Syndrome (LQTS).
The first participants have already enrolled—an important milestone in Thryv’s mission to ensure patient perspectives inform and guide clinical research from the outset.
“Before we can truly transform treatment for LQTS, we need to understand what patients are experiencing every day. myQTwave represents our commitment to putting patients first—not only in the therapies we develop, but in how we approach clinical research itself,” said Dr. Amy Sehnert, Chief Medical Officer of Thryv.
A Study Designed Around Real Life
myQTwave allows adults diagnosed with LQT2 or LQT3 to contribute to cardiac research entirely remotely—using an iPhone and Apple Watch—no clinic visits required. Participants are welcome to join this cardiac research effort from anywhere in the United States.
The study explores how LQTS affects day-to-day life, collecting both physical and emotional well-being data through:
Heart rhythm and activity data via Apple Watch
Patient-Reported Outcome (PRO) measures
Real-world data gathered during daily routines
This expanded approach goes beyond traditional clinical metrics—such as ECG findings and cardiac events—to illuminate how LQTS shapes daily decisions, quality of life, and emotional well-being.
Open for Enrollment
Adults in the U.S. with a confirmed diagnosis of LQT2 or LQT3 and meeting ECG criteria are eligible. To learn more or determine eligibility, visit www.myqtwave.com or see ClinicalTrials.gov (NCT07075445).
Eligibility Snapshot
Adults aged 18 years and older
Confirmed genetic diagnosis of Long QT Syndrome Type 2 (LQT2) or Type 3 (LQT3)
QT prolongation on electrocardiogram (ECG)
Note: myQTwave is a non-interventional observational study and does not replace routine clinical care.’
The myQTwave study is also featured as a research opportunity through the SADS Foundation, a nonprofit organization dedicated to supporting families affected by inherited arrhythmias. Learn more at: https://sads.org/research/get-involved/thryvlqt/.
Built With and For the LQTS Community
myQTwave was developed in collaboration with cardiologists, psychologists, and individuals living with Long QT Syndrome. Patient input informed the study questions, the types of data collected, and how to make remote participation as seamless as possible.
The study’s Principal Investigator is Samuel Sears, PhD, Professor of Clinical Health Psychology at East Carolina University, a leading expert in quality-of-life research in inherited arrhythmias.
"Comprehensive care addresses physical, mental, and social health to deliver the best outcomes for patients. Long QT Syndrome is a rare cardiac disease, and understanding the lived patient experience has been incomplete. Our collaborative team designed this best-in-class study to more accurately capture the realities of living with LQTS," said Dr. Sears.
Part of a Larger Mission
The launch of myQTwave comes as Thryv advances multiple IND programs. The company has recently opened multiple INDs and is preparing to launch Wave II, a Phase 2/3 registration-directed clinical study in LQTS patients anticipated to begin in early 2026.
With SGK1 inhibition representing a novel therapeutic approach for LQTS—a condition affecting approximately 1 in 2,500 people—Thryv’s research efforts are aimed at addressing meaningful unmet needs in genetically defined patient populations.
myQTwave aligns with the FDA’s Patient-Focused Drug Development (PFDD) framework, ensuring that patient voices and experiences help shape future clinical endpoints and treatment strategies.
Reimagining How LQTS Research Is Done
Conducted in collaboration with psychologists at East Carolina University, myQTwave is a self-directed, fully remote, non-interventional observational study enrolling adults with LQT2 or LQT3 and QT prolongation. Participants receive an iPhone, Apple Watch, and a user-friendly app featuring questionnaires designed to understand the whole patient—not just clinical markers.
By integrating connected digital tools, the study will quantify both physical and emotional aspects of living with LQTS, giving patients a direct voice in shaping future research and treatment development.
About Long QT Syndrome
Long QT Syndrome (LQTS) is a rare inherited cardiac disorder characterized by delayed ventricular repolarization, seen on an electrocardiogram (ECG) as a prolonged QT interval. This electrical irregularity increases the risk of torsades de pointes, a potentially life-threatening ventricular arrhythmia, often triggered by physical exertion or emotional stress.
The most common congenital subtypes—LQT1, LQT2, and LQT3—arise from distinct genetic mutations that alter ion channel function and influence arrhythmic risk. LQTS can also be acquired through certain medications that prolong the QT interval and increase arrhythmia risk.
About Thryv Therapeutics
Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). For more information, please visit www.thryvtrx.com.
Media Inquiries
brittany@thryvtrx.com | 514 973 0915
